glp-1 alzheimers How GLP-1s Could Transform Alzheimer's Treatment Novo Nordisk's oral GLP-1 drug

Research published in the New England Journal of Medicine demonstrates that semaglutide achieves remarkable weight reduction: participants lost an average of 14.9% of their body weight at 68 weeks with half achieving at least 15% weight loss and nearly one third losing 20% or more

Despite its importance, many people are deficient in B12, which can lead to a range of health problems, including fatigue, mood swings, and poor cognitive function

PRP requires 1-3 office visits and that's it

Underlying Gastrointestinal Conditions: SIBO can be secondary to other gastrointestinal disorders, such as irritable bowel syndrome (IBS), celiac disease, Crohns disease, or gastroparesis